Business
Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data
Calgary, Alberta--(Newsfile Corp. - July 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and DataCalgary, Alberta--(Newsfile Corp. - July 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (\"Hemostemix\" or the \"Company\") is pleased to announce on June 29, 2020, it filed a Verified Complaint and, on July 2, 2020, Motions for a Preliminary Injunction and Expedited Scheduling seeking to compel the immediate return of all clinical trial data from Defendant Accudata Solutions, Inc. (\"Accudata\") and enjoining Accudata from continuing to divulge and disclose such highly sensitive and confidential information to third parties who have no ownership or custodial right to it.Hemostemix engaged the services of Accudata to conduct, pursuant to a Consulting Agreement executed in August 2019, a statistical analysis of the clinical trial midpoint data. All clinical trial data and, in particular, the clinical trial midpoint analysis and supporting data are, and always have been, the property of Hemostemix. Hemostemix has an absolute ownership right over that data and an absolute right to recover the data upon demand. Despite repeated requests, Accudata has failed and refused to return the midpoint data to Hemostemix.Hemostemix also recently learned that, while refusing to return the clinical trial midpoint data to Hemostemix, Accudata produced a copy of the midpoint data and report to an agent of the former Contract Research Organization (\"CRO\"), Aspire Health Science, LLC (\"Aspire\") and Aspire is now blocking Hemostemix from obtaining the return of its clinical trial data. Neither Aspire nor any of its agents or representatives have any ownership or any other right to have, maintain, or withhold such data, or to hold such data to the exclusion of Hemostemix. Hemostemix seeks the Court's immediate intervention to enjoin Accudata's continued breaches of the parties' agreement.Hemostemix filed in the United States District Court for the District of Delaware. On June 25, 2020 counsel for Hemostemix presented oral argument to the 9th Circuit Court in and for Orange County, Florida on its motion to dismiss Aspire's lawsuit on grounds that, among other things, Hemostemix's threshold challenge that it is not subject to jurisdiction in Florida. A decision on Hemostemix's motion is pending. In the meantime, the pres...